KRAS G12D

Approved therapies

No FDA or EU approvals name KRAS G12D yet.

Drugs in active trials

Targeted drugs, antibody-drug conjugates and immunotherapies in active trials on this page, approved ones first, then by the furthest phase reached. Chemotherapy and supportive medicines are left out. "Not yet classified" means an early drug known only by its code.

25 of 143 drugs shown

Show all 143 drugs

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months: the date the main results are due to be collected, according to the sponsor. Results are usually published months later, and these dates often slip.

Show all 37 readouts

Companies

Industry sponsors leading active trials, by number of trials. Each square is one trial, shaded by phase.

1. Revolution Medicines 10
2. Genfleet Therapeutics 8
3. Jiangsu Hengrui 8
4. Astellas 4
5. Verastem 4
6. Roche 4
7. AstraZeneca 3
8. Eli Lilly 3
9. Incyte 3
10. MSD (Merck & Co.) 3
11. Jiangxi Kvvit Pharmaceutical 2
12. Fosun Pharma 2
13. Ranok Therapeutics 2
14. Abbisko Therapeutics 2
15. Qilu Pharmaceutical 2

Phase 1 Phase 2 Phase 3 Phase 4 No phase

Trials

Matched automatically from registry text, so a few trials may only mention KRAS G12D rather than require it. Check the quoted criterion, and the registry entry before relying on a match.

207 of 448 trials shown

1. Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

   Not yet recruiting Phase 2/3 Jiangxi Kvvit Pharmaceutical Starts 2027Primary completion 2029-02 NCT07656376

   DN022150+AG( Stage I ）DN022150+AG（Stage II）

   Subjects with confirmed KRAS G12D who have not received prior systemic antineoplastic therapy for advanced or metastatic pa…

   Pancreatic Cancer, Pancreatic Carcinoma

2. A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

   Recruiting Phase 3 Genfleet Therapeutics Started 2026Primary completion 2030-06 NCT07668752

   VS-7375docetaxel

   …e to undergo tumor biopsy to obtain tissue samples for central laboratory confirmation of KRAS G12D mutation.

   KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)

3. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

   Recruiting Phase 3 Incyte Started 2026Primary completion 2028-09 NCT07522073

   INCB161734

   Histologically or cytologically confirmed metastatic PDAC with a KRAS G12D mutation

   Solid Tumors

4. A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

   Recruiting Phase 3 Astellas Started 2026Primary completion 2029-08 NCT07409272

   setidegrasiboxaliplatinleucovorinirinotecanfluorouracilliposomal irinotecan

   …G12D mutation based on local or central testing (confirmation of a participant's positive KRAS G12D mutation result must be available prior to randomization).

   Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma

5. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

   Recruiting Phase 3 Revolution Medicines Started 2026Primary completion 2029-03 NCT07805954

   daraxonrasibgemcitabinenab-paclitaxelzoldonrasib

   …ib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

   Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

6. Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

   Recruiting Phase 3 Revolution Medicines Started 2026Primary completion 2029-10 NCT07777822

   zoldonrasibpembrolizumabpemetrexedcisplatincarboplatin

   …herapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

   NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer

7. A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

   Recruiting Phase 3 Astellas Started 2026Primary completion 2030-06 NCT07566052

   setidegrasibdocetaxel

   The participant's positive KRAS G12D mutation result (either in tumor tissue or plasma ctDNA) must be available prior to rando…

   Non-small Cell Lung Cancer (NSCLC)

8. Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

   Not yet recruiting Phase 3 Jiangxi Kvvit Pharmaceutical Started 2026Primary completion 2028-07 NCT07689539

   DN022150Chemotherapy

   Subjects with confirmed KRAS G12D who have received prior systemic therapy for advanced or metastatic pancreatic cancer

   Pancreatic Cancer

9. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   Recruiting Phase 3 Revolution Medicines Started 2026Primary completion 2028-12 NCT07621718

   zoldonrasiboxaliplatinleucovorinfluorouracilirinotecangemcitabinenab-paclitaxel

   … Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

10. HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

    Recruiting Phase 3 Jiangsu Hengrui Started 2025Primary completion 2029-04 NCT07232875

    HRS-4642

    …ne as First-line Treatment for Advanced or Metastatic Pancreatic Adenocarcinoma Harboring KRAS G12D Mutation

    KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

11. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07659782

    VS-7375

    Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

    Non-Small Cell Lung Cancer

12. A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

    Recruiting Phase 2 Genfleet Therapeutics Started 2026Primary completion 2028-08 NCT07784374

    VS-7375GFH276GFS202A

    …reviously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

    Pancreatic Cancer

13. Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

    Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris Started 2026Primary completion 2027-09 NCT07483983

    setidegrasib

    … advanced (unresectable) or metastatic NSCLC (cohort 1) or PDAC (cohort 2) and documented KRAS G12D mutation on the most recent tumor biopsy or circulating tumor DNA (ctDNA) analysis

    Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma

14. To Evaluate the Safety and Efficacy of RNK08954 in Patients With Advanced Gynecological Tumors.

    Not yet recruiting Phase 2 Ranok Therapuetics Started 2026Primary completion 2028-08 NCT07848893

    RNK08954

    Presence of a KRAS G12D mutation.

    Advanced Gynecologic Malignancies

15. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

    Recruiting Phase 1/2 Shenzhen Ionova Life Sciences Started 2026Primary completion 2029-05 NCT07610798

    INV-8989

    …ically confirmed locally advanced, unresectable, or metastatic solid tumors harboring the KRAS G12D mutations.

    Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic

16. A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

    Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University Started 2026Primary completion 2027-10 NCT07438106

    HRS-4642

    KRAS G12D mutation confirmed by tissue histology or peripheral blood testing.

    Locally Advanced Pancreatic Cancer With KRAS G12D Mutation

17. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07659795

    VS-7375cetuximabpanitumumabmFOLFOX6

    Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

    Colorectal Cancer

18. A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

    Recruiting Phase 1/2 Abbisko Therapeutics Started 2026Primary completion 2028-12 NCT07417189

    ABSK141-400mgABSK141-Recommended Dose for Expansion (RDE)ABSK141-800mgABSK141-1200mgABSK141-Recommended Phase 2 dose (RP2D)

    Patients must have the following solid tumor harboring KRAS G12D mutation:

    Solid Tumors, Adult

19. GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

    Not yet recruiting Phase 2 Genfleet Therapeutics Started 2026Primary completion 2027-04 NCT07554859

    VS-7375cetuximabpemetrexed

    Have a written report confirming KRAS G12D mutation positive.

    NSCLC (Advanced Non-small Cell Lung Cancer)

20. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07644559

    VS-7375cetuximabpanitumumab

    Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

    Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS

21. IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

    Recruiting Phase 1/2 InxMed Started 2026Primary completion 2031-02 NCT07441174

    ifebemtinib

    Subjects confirmed to be KRASG12D mutation-positive in tumor tissue samples.

    Solid Tumor Cancer, PDAC

22. HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

    Recruiting Phase 2 Zhejiang University Started 2026Primary completion 2027-05 NCT07240766

    HRS-4642

    Tumor tissue testing confirms KRAS G12D mutation.

    Borderline Resectable Pancreatic Adenocarcinoma

23. To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

    Recruiting Phase 2 Ranok Therapeutics Started 2025Primary completion 2026-11 NCT07303465

    RNK08954

    Presence of a KRAS G12D mutation.

    KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC)

24. Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

    Recruiting Phase 1/2 Anocca Started 2025Primary completion 2030-04 NCT07145450

    ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA allANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA allANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA all

    Confirmed KRAS G12V or KRAS G12D mutation in tumour using biopsy sample.

    PDAC

25. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    Recruiting Phase 1/2 Verastem Started 2025Primary completion 2028-12 NCT07020221

    VS-7375cetuximabcarboplatinpemetrexedpembrolizumabgemcitabinenab-paclitaxeldefactinibmidazolamRepaglinide

    …cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a KRAS G12D mutation.

    Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult

26. HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

    Recruiting Phase 2 Zhejiang University Started 2025Primary completion 2027-02 NCT06770452

    HRS-4642Nimotuzumabgemcitabinenab-paclitaxel

    3.Tumor tissue contains KRAS G12D mutation

    Metastatic Pancreatic Carcinoma

27. A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

    Not yet recruiting Phase 1/2 Qilu Pharmaceutical Started 2025Primary completion 2026-09 NCT06949761

    QLC1101+QL1203QLC1101+QL2107iparomlimab and tuvonralimabdocetaxel

    Subjects confirmed advanced (metastatic or unresectable) solid tumors with KRAS G12D mutations.

    Solid Tumor

28. A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

    Recruiting Phase 1/2 Genfleet Therapeutics Started 2025Primary completion 2027-07 NCT07259590

    VS-7375cetuximabpaclitaxelgemcitabine

    …or cytologically confirmed locally advanced unresectable or metastatic solid tumors, with KRAS G12D mutation.

    Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)

29. A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

    Active, not recruiting Phase 1/2 Arvinas Started 2025Primary completion 2026-11 NCT07023731

    ARV-806

    Must have evidence of KRAS G12D mutation in tumor tissue or blood (circulating tumor deoxyribonucleic acid \[ctDNA\]), AN…

    KRAS G12D Mutation, Advanced Solid Cancer

30. A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    Recruiting Phase 1/2 Tyligand Pharmaceuticals Started 2024Primary completion 2026-10 NCT06385925

    TSN1611paclitaxeloxaliplatinfluorouracilleucovorin

    …logically or cytologically confirmed locally advanced or metastatic solid tumor harboring KRAS G12D mutation

    Malignant Neoplasm

31. A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

    Recruiting Phase 1/2 Genfleet Therapeutics Started 2024Primary completion 2028-07 NCT06500676

    VS-7375

    …h histologically or cytologically confirmed advanced or metastatic solid tumors harboring KRAS G12D mutation.

    KRAS G12D Mutations, Advanced Solid Tumors

32. A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

    Recruiting Phase 1/2 Ranok Therapeutics Started 2024Primary completion 2026-12 NCT06667544

    RNK08954-01

    Must have pathologically documented locally advanced or metastatic malignancy harboring KRAS G12D mutations identified through deoxyribonucleic acid (DNA) sequencing of tumor tissues or c…

    KRAS G12D Mutation

33. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    Recruiting Phase 1/2 Revolution Medicines Started 2024Primary completion 2028-09 NCT06445062

    daraxonrasibmFOLFOX6bevacizumabmFOLFIRINOXcetuximabgemcitabinenab-paclitaxelzoldonrasibFOLFIRI

    Presence of RAS G12D mutation (Subprotocol D, E, F, G)

    Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC

34. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    Recruiting Phase 1/2 Revolution Medicines Started 2024Primary completion 2027-06 NCT06162221

    elironrasibdaraxonrasibpembrolizumabcisplatincarboplatinpemetrexedzoldonrasib

    Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)

    Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

35. A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    Active, not recruiting Phase 1/2 Jiangsu Hengrui Started 2024Primary completion 2025-12 NCT06385678

    HRS-4642adebrelimabSHR-9839pemetrexedcisplatincarboplatincetuximab

    With unresectable locally advanced or metastatic solid tumors harbouring with KRAS G12D mutation confirmed by central laboratory testing.

    Advanced KRAS G12D Mutant Solid Tumors

36. iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

    Recruiting Phase 1/2 M.D. Anderson Cancer Center Started 2021Primary completion 2027-04 NCT03608631

    Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

    …ients with histologically confirmed metastatic pancreatic ductal adenocarcinoma harboring KrasG12D mutation

    KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

37. Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

    Not yet recruiting Phase 1 Leadingtac Pharmaceutical (Shaoxing) Started 2026Primary completion 2028-04 NCT07624214

    LT-010391

    …icipants with histologically or cytologically confirmed advanced solid tumors harboring a KRAS G12D mutation;

    Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

38. A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

    Recruiting Phase 1 D3 Bio Started 2026Primary completion 2028-01 NCT07456046

    D3S-003

    Subjects must have documented presence of KRAS p.G12D mutation by a local test identified through tumor tissue or blood collected within the la…

    KRAS P.G12D

39. A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

    Recruiting Phase 1 Bayer Started 2026Primary completion 2029-07 NCT07535112

    BAY 3771249cetuximab

    KRAS G12D mutated solid tumor

    Advanced/Metastatic Colorectal Adenocarcinoma

40. FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

    Recruiting Phase 1 Memorial Sloan Kettering Cancer Center Started 2026Primary completion 2030-06 NCT07638371

    MSK-TCR5

    Positive for RAS G12D mutation and HLA-A\*11:01 allele

    Solid Tumor, Solid Carcinoma, Advanced Solid Tumor, Unresectable Solid Tumor

41. Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

    Recruiting Phase 1 National Cancer Institute (NCI) Started 2026Primary completion 2029-04 NCT06904066

    aldesleukincyclophosphamidefludarabineIndividual Patient TCR-Transduced PBL

    Targeted mutation - Ras G12D

    Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer

42. A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors

    Not yet recruiting Phase 1 Beijing DCTY Biotech Started 2026Primary completion 2028-08 NCT07014878

    TCR-T cells

    2) Tumor KRAS/NRAS G12D mutation is positive

    Colorectal Cancer, Lung Cancer, Pancreatic Cancer

43. A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma

    Not yet recruiting Phase 1 Roche Started 2026Primary completion 2029-03 NCT07859085

    GDC-7035panitumumabmFOLFOX6FOLFIRImFOLFIRINOXGem-nabP

    Confirmed presence of the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutation as documented through central laboratory testing or prior local laboratory testi…

    Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma

44. Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

    Recruiting Phase 1 Jiangsu Hengrui Started 2025Primary completion 2028-05 NCT07134998

    HRS-6093

    Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

    Advanced KRAS G12D Mutant Solid Tumors

45. A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    Active, not recruiting Phase 1 Incyte Started 2025Primary completion 2027-03 NCT06818812

    INCB186748cetuximabGEMNabPmFOLFIRINOX

    Locally advanced or metastatic solid tumor with KRAS G12D mutation.

    Solid Tumors

46. A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

    Not yet recruiting Phase 1 Hansoh Pharma Started 2025Primary completion 2029-04 NCT06963398

    HS-10529

    A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

    Advanced Solid Tumors

47. A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

    Recruiting Phase 1 Kumquat Biosciences Started 2025Primary completion 2026-09 NCT07207707

    KQB548

    Pathologically confirmed, locally advanced or metastatic PDAC, CRC, or NSCLC with a KRAS G12D mutation

    Solid Tumor Malignancies

48. NW-301 TCR-T in Patients With Advanced Solid Tumor

    Not yet recruiting Phase 1 Peking University Started 2025Primary completion 2026-12 NCT06956261

    NW-301VDrug: NW-301D

    HLA-A\*11:01 positive Tumor tissue samples. sample was positive for KRAS G12V or G12D mutation

    Tumor, Solid

49. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

    Active, not recruiting Phase 1 Eli Lilly Started 2024Primary completion 2028-03 NCT06586515

    LY3962673cetuximabgemcitabinenab-paclitaxeloxaliplatinleucovorinirinotecanfluorouracil

    Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA

    Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

50. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    Recruiting Phase 1 Incyte Started 2024Primary completion 2027-01 NCT06179160

    INCB161734cetuximabretifanlimabGEMNabPmFOLFIRINOXFOLFOXFOLFIRIINCA33890

    Locally advanced or metastatic solid tumor with KRAS G12D mutation.

    Solid Tumors

51. A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

    Recruiting Phase 1 PAQ Therapeutics Started 2024Primary completion 2026-12 NCT06797336

    PT0253Chemotherapy Combination 1Chemotherapy Combination 2Chemotherapy Combination 3cetuximab

    …rticipant has a pathologically documented, locally advanced or metastatic malignancy with KRAS p.G12D mutation identified through molecular testing using a Clinical Laboratory Improvement Ame…

    Solid Tumor

52. Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

    Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2024Primary completion 2029-02 NCT06253520

    aldesleukinfludarabinecyclophosphamideKRAS TCR-Transduced PBLGRT-C903/GRT-R904

    …rian, non-small cell lung cancer (NSCLC) and other solid cancers) with known KRAS G12V or G12D mutation.

    Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer

53. T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

    Active, not recruiting Phase 1 TingBo Liang Started 2024Primary completion 2025-06 NCT06478251

    NW-301VNW-301D

    Tumor has KRAS G12V (NW-301V cohort) or G12D (NW-301D cohort) mutation

    Tumor, Solid

54. T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

    Recruiting Phase 1 Tao Zhang Started 2024Primary completion 2026-06 NCT06484556

    NW-301VNW-301D

    Tumor has KRAS G12V (NW-301V cohort) or G12D (NW-301D cohort) mutation

    Tumor, Solid

55. QTX3046 in Patients With KRAS G12D Mutations

    Active, not recruiting Phase 1 Quanta Therapeutics Started 2024Primary completion 2027-07 NCT06428500

    QTX3046cetuximab

    Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutations identified through molecular testing (NGS- or PCR-based) with a Clinical Labora…

    Advanced Solid Tumor

56. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

    Recruiting Phase 1 AstraZeneca Started 2024Primary completion 2027-08 NCT06218914

    NT-112: Autologous, engineered T Cells targeting KRAS G12DAZD0240: Autologous, engineered T Cells targeting KRAS G12D

    Tumors must harbor a KRAS G12D variant mutation and subject must be HLA-C\*08:02 positive, HLA-A\*11:01 or HLA-A\*11:02 …

    Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer

57. T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

    Recruiting Phase 1 Ting Deng Started 2024Primary completion 2026-04 NCT06484790

    NW-301VNW-301D

    HLA-A11:01positive Tumor has KRAS G12V (NW-301V cohort) or G12D (NW-301D cohort) mutation \* Adequate organ function prior to apheresis and lymphodepleti…

    Tumor, Solid

58. A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

    Recruiting Phase 1 Roche Started 2024Primary completion 2028-05 NCT06619587

    Phase I Arm APhase I Arm B

    Histologically documented advanced or metastatic solid tumor with KRAS G12D mutation

    Solid Tumor

59. QTX3034 in Patients With KRAS G12D Mutation

    Recruiting Phase 1 Quanta Therapeutics Started 2024Primary completion 2027-04 NCT06227377

    QTX3034cetuximab

    Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laborat…

    Solid Tumors

60. A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

    Recruiting Phase 1 Qilu Pharmaceutical Started 2024Primary completion 2026-05 NCT06403735

    QLC1101

    …h histologically confirmed advanced (metastatic or unresectable) solid tumors harboring a KRAS G12D mutation.

    Status may be outdated, last updated 2024-05-08Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor

61. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    Recruiting Phase 1 Revolution Medicines Started 2023Primary completion 2026-12 NCT06040541

    zoldonrasibdaraxonrasib

    Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation

    Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

62. A Study of ASP3082 in Adults With Advanced Solid Tumors

    Recruiting Phase 1 Astellas Started 2022Primary completion 2028-12 NCT05382559

    setidegrasibcetuximableucovorinoxaliplatinfluorouracilirinotecannab-paclitaxelgemcitabinedocetaxelpembrolizumabcisplatincarboplatin

    … lung cancer (NSCLC) (Note: for Cohort H only, the tumor must be non-squamous NSCLC) with KRAS G12D mutation and

    Solid Tumor

63. KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

    Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2022Primary completion 2027-04 NCT05254184

    nivolumabipilimumabcarboplatinpaclitaxelpemetrexed

    Have one of the KRAS mutations (KRASG12C, KRASG12V, KRASG12D, KRASG12A, KRASG13D or KRASG12R) included in the vaccine at the time of vaccination expre…

    Non-Small Cell Lung Cancer

64. Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    Active, not recruiting Phase 1 Jiangsu Hengrui Started 2022Primary completion 2024-06 NCT05533463

    HRS-4642

    Histologically confirmed diagnosis of advanced solid tumor harbouring with KRAS G12D mutation

    Advanced KRAS G12D Mutant Solid Tumors

65. TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

    Not yet recruiting Early Phase 1 Sun Yat-sen University Started 2026Primary completion 2028-02 NCT07342738

    TCR-T cellsfludarabinecyclophosphamide

    Patients with tumor tissue or peripheral blood testing positive for KRAS-G12V or G12D mutations and expression of matching HLA-A\*11:01 or HLA-C\*01:02 subtypes;

    KRAS G12V, KRAS G12D, Solid Tumor

66. Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)

    Not yet recruiting Phase 3 Fudan University Started 2026Primary completion 2028-12 NCT07362836

    fruquintinibbevacizumab

    RAS mutant type.

    Broad match: KRAS mutation (unspecified)Colorectal Cancer

67. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    Recruiting Phase 3 Revolution Medicines Started 2025Primary completion 2027-12 NCT06881784

    daraxonrasibdocetaxel

    Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).

    Broad match: KRAS mutation (unspecified)NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

68. Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

    Active, not recruiting Phase 3 Revolution Medicines Started 2024Primary completion 2026-06 NCT06625320

    daraxonrasibgemcitabinenab-paclitaxelirinotecanliposomal irinotecanfluorouracilleucovorinoxaliplatin

    RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, …

    Broad match: KRAS mutation (unspecified)Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

69. Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

    Recruiting Phase 3 Caigang Liu Started 2024Primary completion 2026-02 NCT06566755

    cadonilimabbevacizumab

    Genetic testing revealed RAS (including KRAS and NRAS) mutations, or primary sites located in the right half of the colon (including cecum, rising Colon a…

    Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-08-22Colorectal Cancer

70. A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

    Not yet recruiting Phase 2/3 Jiangsu Hengrui Started 2024Primary completion 2028-10 NCT06335355

    adebrelimabpemetrexedcarboplatincamrelizumab

    Participants must have tumors with STK11 or KEAP1 or KRAS mutations.

    Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-03-28Non-squamous Non-small Cell Lung Cancer

71. Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

    Active, not recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine Started 2022Primary completion 2026-12 NCT05171660

    sintilimabbevacizumaboxaliplatincapecitabine

    RAS mutation, BRAF V600E wild type, and microsatellite stable

    Broad match: KRAS mutation (unspecified)Colorectal Cancer Stage IV

72. A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

    Active, not recruiting Phase 3 Eli Lilly Started 2014Primary completion 2017-09 NCT02152631

    abemacicliberlotinib

    A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

    Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer

73. Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

    Active, not recruiting Phase 3 AstraZeneca Started 2013Primary completion 2016-06 NCT01933932

    selumetinibdocetaxelpegfilgrastim

    KRAS mutation positive tumour sample as determined by the designated testing laboratory

    Broad match: KRAS mutation (unspecified)Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

74. A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

    Not yet recruiting Phase 1/2 M.D. Anderson Cancer Center Starts 2027Primary completion 2028-06 NCT07053020

    cytarabinecladribine

    …AML-M5 by FAB or flow cytometry, and/or patients . 60 years with newly diagnosed AML with RAS mutations.

    Broad match: KRAS mutation (unspecified)Acute Myeloid Leukemia (AML)

75. Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

    Recruiting Phase 1/2 National Cancer Institute (NCI) Starts 2027Primary completion 2028-09 NCT07619521

    selumetinibtrastuzumab deruxtecan

    Patients must have unresectable or metastatic disease with KRAS mutation per Next Generation Sequencing (NGS) tumor testing and HER2 immunohistochemistry (IHC) po…

    Broad match: KRAS mutation (unspecified)Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8

76. Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

    Not yet recruiting Phase 2 Nationwide Children's Hospital Starts 2027Primary completion 2030-02 NCT07206849

    tovorafenib

    KRAS/NRAS alteration (Strata B or C)

    Broad match: KRAS mutation (unspecified)High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine Glioma, High Grade Glioma

77. Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations

    Not yet recruiting Phase 1/2 Children's Oncology Group Starts 2027Primary completion 2032-04 NCT07819838

    daraxonrasib

    PARTS A1 AND A2: Patients with relapsed or refractory RAS mutant extracranial solid tumors

    Broad match: KRAS mutation (unspecified)Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma, Recurrent Childhood Rhabdomyosarcoma, Refractory Childhood Malignant Solid Neoplasm

78. This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.

    Not yet recruiting Phase 1/2 Genfleet Therapeutics Started 2026Primary completion 2027-12 NCT07846358

    GFH276tislelizumabpemetrexedcisplatincarboplatin

    Confirmed RAS mutation or KRAS amplification；tumor cell PD L1 test report available

    Broad match: KRAS mutation (unspecified)RAS Mutation, Non-small Cell Lung Cancer (NSCLC)

79. A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

    Recruiting Phase 1/2 Blueprint Medicines Started 2026Primary completion 2029-09 NCT07629960

    BLU-924

    …cell lung cancer (NSCLC), or colorectal cancer (CRC) with evidence of a single KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor deoxyribonucleic…

    Broad match: KRAS G12DAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma

80. LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

    Not yet recruiting Phase 1/2 Luye Pharma Group Started 2026Primary completion 2028-12 NCT07391566

    LPM6690176bevacizumabFOLFIRIfluorouracilleucovorinirinotecan

    Histologically confirmed metastatic colorectal cancer (CRC) with RAS mutation;

    Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer (mCRC)

81. A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

    Recruiting Phase 2 Fosun Pharma Started 2026Primary completion 2029-06 NCT07562581

    luvometinibanlotinib

    KRAS mutation positive.

    Broad match: KRAS mutation (unspecified)Non-small Cell Lung Caner, KRAS-mutated, Metastasis, Previous Treamted

82. CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

    Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2026Primary completion 2029-12 NCT07383285

    iparomlimab and tuvonralimabcapecitabinebevacizumaboxaliplatin

    The genetic test results were KRAS or NRAS mutations, without BRAF V600 mutations, and the immunohistochemical results were pMMR;

    Broad match: KRAS mutation (unspecified)Rectal Neoplasms Malignant

83. GST101 in Participants With RAS-Mutant Advanced Solid Tumors

    Not yet recruiting Phase 1/2 Genuine Seed Therapeutics Started 2026Primary completion 2028-10 NCT07868172

    GST101

    Histologically or cytologically confirmed RAS-mutated advanced solid tumor, with disease progression or intolerance to standard anti-tumor ther…

    Broad match: KRAS mutation (unspecified)RAS-mutant Advanced Solid Tumors

84. Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

    Not yet recruiting Phase 2 Chinese PLA General Hospital Started 2026Primary completion 2027-10 NCT07446270

    cetuximabPancreatic cancer: Tunlametinib +Nimotuzumab

    Genetic testing demonstrating RAS mutation;

    Broad match: KRAS mutation (unspecified)Treatment for Advanced Colorectal Cancer, Treatment for Advanced Pancreatic Cancer

85. A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

    Not yet recruiting Phase 2 Dai, Guanghai Started 2026Primary completion 2029-04 NCT07797244

    XELOXbevacizumab

    RAS-mutant;

    Broad match: KRAS mutation (unspecified)Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

86. A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

    Not yet recruiting Phase 1/2 Zhejiang University Started 2026Primary completion 2028-08 NCT07736612

    HRS-2329 TabletNimotuzumabHS-20093adebrelimab

    RAS mutation or amplification detected in tumor tissue or blood (by RAS testing).

    Broad match: KRAS mutation (unspecified)Pancreatic Cancer, RAS Mutations or Amplifications

87. A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

    Recruiting Phase 1/2 Genfleet Therapeutics Started 2026Primary completion 2027-11 NCT07678593

    GFH276cetuximabnab-paclitaxelgemcitabinefluorouracilleucovorinirinotecanoxaliplatin

    …cally or cytologically confirmed locally advanced or metastatic solid tumor and PDAC with RAS mutation or KRAS amplification

    Broad match: KRAS mutation (unspecified)Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation

88. FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

    Recruiting Phase 2 Oncolytics Biotech Started 2026Primary completion 2027-08 NCT07446322

    bevacizumabFOLFIRIPelareorep

    Tumor confirmed to harbor a known RAS mutation per a standard local testing method

    Broad match: KRAS mutation (unspecified)Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer

89. A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

    Recruiting Phase 1/2 MSD (Merck & Co.) Started 2026Primary completion 2029-08 NCT07286149

    calderasibpatritumab deruxtecansacituzumab tirumotecancetuximabRescue Medications

    …ucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene (KRAS) mutation of glycine to cysteine at codon 12 (G12C) mutations

    Broad match: KRAS mutation (unspecified)Lung Neoplasm Malignant

90. KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer

    Recruiting Phase 1/2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Started 2026Primary completion 2029-01 NCT07353645

    KRAS Neoantigen Nanovaccine

    The tumor must harbor at least one of the following KRAS hotspot mutations: G12D, G12V, G12R, G12A, G12S, G12C, or G13D.

    Broad match: KRAS G12DColorectal Cancer, Pancreatic Cancer

91. TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients

    Not yet recruiting Phase 1/2 Tango Therapeutics Started 2026Primary completion 2031-11 NCT07897734

    vopimetostatERAS-0015

    …ed, recurrent or metastatic NSCLC (no more than 2 prior lines of therapy) with documented KRAS mutation at G12X or G13X locally obtained via an analytically validated assay (Dose expansion only…

    Broad match: KRAS mutation (unspecified)PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation

92. Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

    Not yet recruiting Phase 1/2 BOE Technology Group Started 2026Primary completion 2028-04 NCT07551778

    NK CellspemetrexedcetuximabbevacizumabcapecitabineNK cells + PD-(L)1 inhibitor + VEGF inhibitor as first-line maintenance therapy

    …: EGFR sensitive mutations, ALK gene rearrangements, ROS1 mutations, BRAF 600E mutations, KRAS mutations);

    Broad match: KRAS mutation (unspecified)NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC)

93. Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Recruiting Phase 1/2 Betta Pharmaceuticals Started 2026Primary completion 2028-12 NCT07435038

    BPI-572270

    Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing.

    Broad match: KRAS mutation (unspecified)Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

94. Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Not yet recruiting Phase 2 Sun Yat-sen University Started 2026Primary completion 2028-05 NCT07463677

    cetuximabfulzerasib

    Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Broad match: KRAS mutation (unspecified)Lung Cancer (NSCLC)

95. Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

    Not yet recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2026Primary completion 2030-11 NCT07793253

    daraxonrasib

    Documented KRAS mutation

    Broad match: KRAS mutation (unspecified)Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma

96. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    Recruiting Phase 1/2 Revolution Medicines Started 2026Primary completion 2029-05 NCT07397338

    daraxonrasibelironrasibzoldonrasibivonescimabcarboplatincisplatinpemetrexedcetuximab

    …ogically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.

    Broad match: KRAS mutation (unspecified)Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC

97. An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

    Recruiting Phase 1/2 Jiangsu Hengrui Started 2026Primary completion 2028-12 NCT07806058

    adebrelimabHRS-7172 + AG;HRS-4642

    …ocally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood genetic testing.

    Broad match: KRAS mutation (unspecified)Pancreatic Cancer

98. Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

    Recruiting Phase 1/2 University of California, Irvine Started 2025Primary completion 2029-12 NCT07064018

    Spedox-6pegfilgrastim

    …lative to normal tissue including: STS, TNBC, cervical cancer, NSCLC, ovarian cancer, and KRAS mutated pancreatic ductal adenocarcinoma without requirement for testing FcRn level.

    Broad match: KRAS mutation (unspecified)Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer

99. Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

    Recruiting Phase 2 Buzzard Pharmaceuticals Started 2025Primary completion 2027-06 NCT06634875

    isunakinra

    Tumor is determined to be RAS-mutated (KRAS, NRAS or HRAS) and microsatellite stable/proficient in mismatch repair, as assessed…

    Broad match: KRAS mutation (unspecified)Colorectal Cancer Metastatic

100. STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

     Recruiting Phase 2 National Cancer Institute, Naples Started 2025Primary completion 2026-10 NCT07213570

     standard second line treatment, at discretion of the investigatorregorafenib

     RAS mutant at initial diagnosis assessed at local centers according with a validated method defined …

     Broad match: KRAS mutation (unspecified)Colorectal Cancer Metastatic

101. Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

     Recruiting Phase 1/2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2025Primary completion 2028-12 NCT06782932

     AGEN2373balstilimabcyclophosphamideGVAXmKRASvax

     A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resec…

     Broad match: KRAS mutation (unspecified)Pancreatic Cancer

102. Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

     Recruiting Phase 2 Fudan University Started 2025Primary completion 2026-08 NCT06521866

     serplulimabChemotherapyTargeted therapy

     …mary tumor located in the cecum, ascending colon, and proximal transverse colon, and RAS (KRAS and NRAS) mutant-type (Cohorts C and D);

     Broad match: KRAS mutation (unspecified)Advanced Colorectal Carcinoma, Immunotherapy

103. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

     Recruiting Phase 1/2 Tango Therapeutics Started 2025Primary completion 2027-06 NCT06922591

     TNG462zoldonrasibdaraxonrasibmFOLFIRINOXgemcitabinenab-paclitaxel

     Arms A and B only: Has a tumor with a RAS mutation

     Broad match: KRAS mutation (unspecified)PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation

104. A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

     Recruiting Phase 1/2 Bristol Myers Squibb Started 2025Primary completion 2028-10 NCT07223047

     BMS-986523gemcitabinenab-paclitaxelcetuximabpembrolizumab

     …etastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).

     Broad match: KRAS mutation (unspecified)Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

105. Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

     Recruiting Phase 2 Sergey Orlov, MD Started 2025Primary completion 2027-04 NCT06949982

     experimental group x-MAPregorafenib

     Presence of mutations in the KRAS or NRAS gene.

     Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms

106. Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

     Recruiting Phase 1/2 Auricula Biosciences Started 2025Primary completion 2028-01 NCT07148128

     WEF-001

     Advanced KRAS-mutant solid tumor: pancreatic ductal adenocarcinoma, colorectal cancer, non small cell lung can…

     Broad match: KRAS mutation (unspecified)Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors

107. Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

     Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2025Primary completion 2026-12 NCT07007728

     Iparomlimab/Tuvonralimabbevacizumab

     Genetic testing results confirming either RAS mutation or right-sided colon location with RAS wild-type status, absence of BRAF V600E mutation, …

     Broad match: KRAS mutation (unspecified)Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver

108. A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

     Not yet recruiting Phase 1/2 Genfleet Therapeutics Started 2025Primary completion 2027-09 NCT07198321

     GFH276

     … Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

     Broad match: KRAS mutation (unspecified)Cancer, PDAC, CRC (Colorectal Cancer), NSCLC

109. Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

     Recruiting Phase 2 Guangzhou JOYO Pharma Started 2025Primary completion 2026-03 NCT06895031

     JYP0015

     Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.

     Broad match: KRAS mutation (unspecified)Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)

110. A Clinical Study of Arfolitixorin in Patients With mCRC

     Recruiting Phase 1/2 Isofol Medical Started 2025Primary completion 2028-11 NCT06922383

     Arfolitixorin

     Phase 1b: Histologically confirmed RAS mutant, MSS/pMMR, colorectal adenocarcinoma with metastatic disease, eligible for first-line the…

     Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer (mCRC)

111. SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

     Not yet recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University Started 2025Primary completion 2027-02 NCT06835179

     PD-1 Inhibitorsbevacizumab

     RAS mutation-positive.

     Broad match: KRAS mutation (unspecified)Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer

112. XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

     Enrolling by invitation Phase 1/2 Fosun Pharma Started 2025Primary completion 2028-04 NCT06936527

     bevacizumabFOLFOXFOLFIRIDrug: XS-03

     Documentation of RAS mutation.

     Broad match: KRAS mutation (unspecified)Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation

113. Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

     Recruiting Phase 1/2 Sichuan Huiyu Pharmaceutical Started 2024Primary completion 2026-12 NCT06243354

     Test product: HYP-2090PTSA

     Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

     Broad match: KRAS mutation (unspecified)Safety, Tolerability, Efficacy

114. Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

     Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Started 2024Primary completion 2027-10 NCT06686108

     azacitidinedecitabinevenetoclax

     High risk subgroups based on NGS definition: PI3K signaling pathway/NRAS, KRAS/TP53/IKZF1/DNTM3A/IDH1, IDH2 gene mutation with or without NOTCH1, FBXW7/PHF6/EP300 gene mutation.

     Broad match: KRAS mutation (unspecified)T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse

115. Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

     Recruiting Phase 2 Ruijin Hospital Started 2024Primary completion 2026-02 NCT06368141

     serplulimabcapecitabineoxaliplatin

     MSS/RAS mutation patients with clinical stages T3N1-2 and T4N0-2

     Broad match: KRAS mutation (unspecified)Colon Cancer

116. Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

     Recruiting Phase 2 Shanghai Chest Hospital Started 2024Primary completion 2025-11 NCT06659042

     tislelizumabcisplatincarboplatinpemetrexed

     With Known KRAS gene mutation.

     Broad match: KRAS mutation (unspecified)Lung Cancer, Non-Small Cell

117. A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

     Active, not recruiting Phase 2 AstraZeneca Started 2024Primary completion 2026-10 NCT06008093

     durvalumabtremelimumabpemetrexedpembrolizumabcarboplatincisplatin

     Participants must have tumors with STK11 or KEAP1 or KRAS mutations.

     Broad match: KRAS mutation (unspecified)Carcinoma, Non-Small-Cell Lung

118. Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

     Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024Primary completion 2026-12 NCT06440954

     pemetrexed

     …fusion, and other oncogenic alterations including RET fusion, BRAF mutation, NTRK fusion, KRAS mutation was confirmed by an accredited local laboratory.

     Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-06-04Non-Small Cell Lung Cancer

119. Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

     Recruiting Phase 2 Fudan University Started 2024Primary completion 2025-12 NCT06218810

     cadonilimabbevacizumabFOLFOX

     RAS mutation;

     Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-01-23Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab

120. Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

     Recruiting Phase 2 Emory University Started 2024Primary completion 2029-03 NCT06495125

     avutometinibdefactinibnivolumab

     COHORT A ONLY: Patients must have known KRAS mutation

     Broad match: KRAS mutation (unspecified)Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

121. Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

     Not yet recruiting Phase 1/2 Shanghai Chest Hospital Started 2024Primary completion 2026-06 NCT06456138

     trametinibanlotinibtislelizumab

     KRAS mutation positive detected by ARMS or NGS;

     Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-06-13KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor

122. Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

     Active, not recruiting Phase 2 Cardiff Oncology Started 2024Primary completion 2026-11 NCT06106308

     OnvansertibFOLFIRIbevacizumabFOLFOX

     Documented KRAS or NRAS mutation.

     Broad match: KRAS mutation (unspecified)Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation

123. A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

     Recruiting Phase 1/2 Jacobio Pharmaceuticals Started 2024Primary completion 2026-12 NCT06959615

     JAB-23E73

     …f a locally advanced, unresectable, and/or metastatic solid tumor cancer with evidence of KRAS gene alteration (including gene mutation and wild type amplification).

     Broad match: KRAS mutation (unspecified)Advanced Solid Tumor

124. A Study of Avutometinib and Defactinib in People With Thyroid Cancer

     Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2023Primary completion 2027-08 NCT06007924

     avutometinibdefactinib

     …ecurrent tumor, or metastases) possess at least one of the following genetic alterations: RAS mutation, NF1 mutation, RET rearrangement, NTRK rearrangement, ALK rearrangement, Class 2 or 3 BRA…

     Broad match: KRAS mutation (unspecified)Thyroid Cancer

125. A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

     Active, not recruiting Phase 1/2 Elicio Therapeutics Started 2023Primary completion 2026-04 NCT05726864

     ELI-002

     KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor

     Broad match: KRAS G12DPancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R

126. Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2023Primary completion 2028-08 NCT05554367

     binimetinibpalbociclib

     Patients must have KRAS/NRAS/HRAS or RAF mutations or rare RAF fusions as determined by the ComboMATCH screening assessment

     Broad match: KRAS mutation (unspecified)Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8

127. The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

     Recruiting Phase 1/2 Oslo University Hospital Started 2023Primary completion 2027-05 NCT05841550

     TG01

     RAS mutation (KRAS/NRAS codon 12/13 mutation) detected on archival or fresh bone marrow material with …

     Broad match: KRAS mutation (unspecified)Multiple Myeloma, Smoldering Multiple Myeloma

128. Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2023Primary completion 2026-09 NCT05554328

     olaparibselumetinib

     …hway mutant ovarian, primary peritoneal, or fallopian tube ("ovarian") cancer (activating mutations in KRAS, NRAS, HRAS, BRAF, MEK1, MEK2, or inactivating mutations in NF1)

     Broad match: KRAS mutation (unspecified)Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

129. Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

     Recruiting Phase 1/2 Genfit Started 2023Primary completion 2027-12 NCT05874414

     trametinib

     Histologically confirmed intrahepatic CCA with a documented KRAS mutation.

     Broad match: KRAS mutation (unspecified)Cholangiocarcinoma

130. A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

     Recruiting Phase 2 University of Oklahoma Started 2023Primary completion 2027-12 NCT05512208

     avutometinibdefactinib

     Tumor with known RAS mutation, BRAF (type I, II, and/or III) mutation, NF-1 and/or RAS activation status determined fro…

     Broad match: KRAS mutation (unspecified)Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer

131. Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA

     Recruiting Phase 2 Fudan University Started 2023Primary completion 2028-09 NCT06440902

     cetuximab

     Metastatic colorectal cancer with tissue RAS mutation-type;

     Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-06-04Colorectal Cancer Metastatic

132. FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

     Recruiting Phase 2 Sun Yat-sen University Started 2022Primary completion 2026-12 NCT05727163

     dexamethasoneanisodamineoxaliplatinleucovorinfluorouracilirinotecanbevacizumab

     …us Systemic FOLFOXIRI With or Without Bevacizumab in Patients With Initially Unresectable RAS-mutated Colorectal Cancer With Liver Metastases: A Prospective, Randomized, Controlled Clinical S…

     Broad match: KRAS mutation (unspecified)Colorectal Cancer Metastatic

133. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

     Recruiting Phase 1/2 Revolution Medicines Started 2022Primary completion 2027-05 NCT05379985

     daraxonrasib

     …ally confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing.

     Broad match: KRAS mutation (unspecified)Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

134. Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

     Active, not recruiting Phase 2 University of Kansas Medical Center Started 2022Primary completion 2024-12 NCT05638698

     TG01QS-21balstilimab

     Screening tumor tissue positive or known pathogenic or likely pathogenic RAS mutation resulting in amino acid substitution in codon 12A, 12C, 12D, 12R, 12S or 13D .

     Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-09-23Pancreas Cancer

135. Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2022Primary completion 2026-12 NCT05327010

     ZEN-3694talazoparib

     Patients in Cohort 4 must have KRAS mutated advanced solid tumors.

     Broad match: KRAS mutation (unspecified)Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

136. A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

     Active, not recruiting Phase 1/2 Immuneering Started 2022Primary completion 2027-06 NCT05585320

     atebimetinibgemcitabinenab-paclitaxelFOLFIRINOXdabrafenibpembrolizumab

     …sectable or metastatic solid tumor malignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non-small cell lung cancer (NSCLC)

     Broad match: KRAS mutation (unspecified)Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)

137. A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

     Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2022Primary completion 2027-10 NCT05118854

     sotorasibcisplatincarboplatinpemetrexed

     …ng method \[including droplet-digital PCR, real-time PCR based methods such as the Idylla KRAS Mutation Assay (Biocartis), tissue and circulating tumor DNA -based next generation sequencing, Sa…

     Broad match: KRAS mutation (unspecified)Lung Cancer

138. Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

     Recruiting Phase 1/2 Sellas Life Sciences Group Started 2021Primary completion 2026-12 NCT04588922

     SLS009venetoclaxazacitidine

     KRASmut: 1 point

     Broad match: KRAS mutation (unspecified)Hematologic Malignancies

139. Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

     Active, not recruiting Phase 2 David E Gerber Started 2019Primary completion 2025-04 NCT03808558

     TVB-2640

     …histologically or cytologically confirmed NSCLC and molecular identification of oncogenic KRAS mutation.

     Broad match: KRAS mutation (unspecified)KRAS Gene Mutation

140. Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2018Primary completion 2025-07 NCT03600701

     atezolizumabcobimetinib

     Presence of a mutation in KRAS as detected by a Clinical Laboratory Improvement Act (CLIA)-approved assay is required fo…

     Broad match: KRAS mutation (unspecified)Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

141. Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

     Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2017Primary completion 2027-01 NCT03087071

     panitumumabtrametinib

     may have a concomitant mutation in KRAS, NRAS, or BRAF, if there is at least a 5-fold higher allele frequency of the most prevale…

     Broad match: KRAS mutation (unspecified)EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma

142. Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

     Recruiting Phase 1/2 National Cancer Institute (NCI) Started 2017Primary completion 2027-06 NCT03190941

     cyclophosphamidefludarabineAnti-KRAS G12V mTCR PBLaldesleukin

     …surable (per RECIST V1.1 criteria, metastatic, or unresectable malignancy expressing G12V mutated KRAS as assessed by one of the following methods: RT-PCR on tumor tissue, tumor DNA sequencing…

     Broad match: KRAS mutation (unspecified)Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer

143. Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2016Primary completion 2019-05 NCT02642042

     docetaxeltrametinib

     DISEASE RELATED CRITERIA: Patients must have pathologically confirmed KRAS mutation (at codon 12, 13 and 61) positive non-small cell lung cancer (NSCLC) that is stage IV or …

     Broad match: KRAS mutation (unspecified)KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

144. Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

     Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2014Primary completion 2022-12 NCT02079740

     navitoclaxtrametinib

     Patients must have histologically- or cytologically-confirmed diagnosis of KRAS or NRAS mutation-positive malignancy that is metastatic or unresectable and for which standard curative me…

     Broad match: KRAS mutation (unspecified)Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

145. Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2014Primary completion 2021-08 NCT02152995

     trametinib

     A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers

     Broad match: KRAS mutation (unspecified)Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma

146. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2013Primary completion 2015-08 NCT01708954

     cabozantiniberlotinib

     …t least one alternative driver mutation, i.e: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, v-raf murine sarcoma viral oncogene homolog B (BRAF) mutation, human epidermal growth fa…

     Broad match: KRAS mutation (unspecified)Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

147. Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

     Recruiting Phase 1 Adlai Nortye Biopharma Started 2026Primary completion 2028-01 NCT07252479

     AN9025 oral capsule

     Documentation of KRAS/NRAS/HRAS mutation determined by validated local testing of tumor tissue or circulating free DNA (cfDNA) in …

     Broad match: KRAS mutation (unspecified)Solid Tumors (Phase 1), RAS Mutation

148. TCR1188-ABC Cells in KRAS-mutated Cancers

     Recruiting Phase 1 University of Pennsylvania Started 2026Primary completion 2042-11 NCT07594067

     TCR1188-ABC cellsfludarabinecyclophosphamidetocilizumab

     TCR1188-ABC Cells in KRAS-mutated Cancers

     Broad match: KRAS mutation (unspecified)Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma

149. Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

     Recruiting Phase 1 M.D. Anderson Cancer Center Started 2026Primary completion 2028-08 NCT07318324

     avutometinibdefactinibeverolimus

     Participants must have histologically or cytologically confirmed recurrent RAS mutant endometrial cancer.

     Broad match: KRAS mutation (unspecified)Phase IB, Avutometinib, RAS Pathway, Endometrial

150. Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer

     Not yet recruiting Phase 1 Sichuan University Started 2026Primary completion 2028-09 NCT07637786

     ONVAX-01 plus Anti-PD-1 and Chemotherapy

     Histologically confirmed, KRAS-mutated, unresectable metastatic pancreatic ductal adenocarcinoma (PDAC).

     Broad match: KRAS mutation (unspecified)Advanced Pancreatic Adenocarcinoma

151. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

     Recruiting Phase 1 Kestrel Therapeutics Started 2026Primary completion 2028-04 NCT07458347

     KST-6051gemcitabinenab-paclitaxelcetuximabpembrolizumabmFOLFOX6FOLFIRIpemetrexedcarboplatin

     Documentation of KRAS mutation prior to the first dose of trial drug(s).

     Broad match: KRAS mutation (unspecified)KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors

152. A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

     Recruiting Phase 1 Memorial Sloan Kettering Cancer Center Started 2026Primary completion 2028-06 NCT07671339

     ELI-002tislelizumabmFOLFIRINOX

     Presence of one of seven KRAS mutations: G12D, G12V, G12R, G12C, G12A, G12S, or G13D.

     Broad match: KRAS G12DPancreatic Cancer

153. Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

     Not yet recruiting Phase 1 Jiangsu Aosaikang Pharmaceutical Started 2026Primary completion 2028-11 NCT07836036

     ASKC189

     Documentation of KRAS/NRAS/HRAS mutation determined by validated local testing of tumor tissue or circulating free DNA (cfDNA) in …

     Broad match: KRAS mutation (unspecified)Solid Tumor, RAS Mutation

154. Study of ABO2102 in KRAS-Mutated Solid Tumors

     Recruiting Phase 1 Suzhou Abogen Biosciences Started 2026Primary completion 2029-06 NCT07455617

     ABO2102 Injectionsintilimab

     …e genetic testing during the screening period, with evidence of harboring any of required KRAS mutations

     Broad match: KRAS mutation (unspecified)Advanced / Metastatic Solid Tumor

155. A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression

     Recruiting Phase 1 Adlai Nortye Biopharma Started 2026Primary completion 2028-12 NCT07686445

     Intravenous AN4035Intravenous AN4035 followed by intravenous EGFR Inhibitor.

     Documentation of KRAS/NRAS/HRAS mutation determined by a Sponsor-approved validated local testing of tumor tissue or cfDNA in a CL…

     Broad match: KRAS mutation (unspecified)Solid Tumor (Phase I), RAS Mutation, CEACAM5

156. A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations

     Recruiting Phase 1 BeOne Medicines (BeiGene) Started 2026Primary completion 2028-09 NCT07746141

     BG-85738tislelizumabcetuximab

     Participants must have evidence of a RAS mutation defined as a nonsynonymous mutation in Kirsten rat sarcoma viral oncogene homolog (KRAS),…

     Broad match: KRAS mutation (unspecified)RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor

157. A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration

     Recruiting Phase 1 Abbisko Therapeutics Started 2026Primary completion 2029-12 NCT07718165

     ABSK211

     …pants with histologically confirmed locally-advanced or metastatic solid tumors harboring KRAS alteration

     Broad match: KRAS mutation (unspecified)Solid Tumor (Phase I)

158. MTX-531-001 Phase 1 Study in Advanced Solid Tumors

     Not yet recruiting Phase 1 MEKanistic Therapeutics Started 2026Primary completion 2028-12 NCT07874880

     MTX-531

     Advanced or metastatic CRC Pan-RAS and BRAF wildtype in tumor and/or ctDNA

     Broad match: KRAS mutation (unspecified)Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer

159. Imatinib and Trametinib for KRAS-mutated Solid Tumor

     Recruiting Phase 1 China Medical University Hospital Started 2025Primary completion 2028-03 NCT06962254

     imatinibtrametinib

     Imatinib and Trametinib for KRAS-mutated Solid Tumor

     Broad match: KRAS mutation (unspecified)Solid Tumor Cancer

160. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

     Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2025Primary completion 2027-08 NCT06917079

     BBO-11818pembrolizumabcisplatincarboplatinpemetrexedcetuximabmFOLFOX6BBO-10203mFOLFIRINOXgemcitabinenab-paclitaxel

     …d unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation

     Broad match: KRAS G12DNon-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)

161. AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

     Recruiting Phase 1 Amgen Started 2025Primary completion 2028-04 NCT07094113

     AMG 410pembrolizumabpanitumumab

     Pathologically documented, locally-advanced or metastatic malignancy with any missense mutation in the KRAS gene or evidence of KRAS amplification using an analytically validated KRASWT amplificati…

     Broad match: KRAS mutation (unspecified)KRAS Altered Advanced or Metastatic Solid Tumors

162. A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

     Recruiting Phase 1 MSD (Merck & Co.) Started 2025Primary completion 2030-12 NCT07247110

     MK-4716pembrolizumabcetuximab

     …716 + Cetuximab: Must demonstrate presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration

     Broad match: KRAS mutation (unspecified)Malignant Neoplasm

163. A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

     Recruiting Phase 1 Jiangsu Hengrui Started 2025Primary completion 2028-12 NCT07142980

     HRS-7172 Tablets

     A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

     Broad match: KRAS mutation (unspecified)Advanced Solid Tumors Harboring RAS Mutations or Amplifications

164. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

     Recruiting Phase 1 Alterome Therapeutics Started 2025Primary completion 2029-05 NCT06835569

     ALTA3263cetuximabmFOLFOX6pembrolizumabpemetrexedcisplatincarboplatinmFOLFIRINOXGnPmidazolam

     Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Impro…

     Broad match: KRAS mutation (unspecified)Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)

165. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

     Recruiting Phase 1 Roche Started 2025Primary completion 2028-08 NCT06884618

     RO7673396

     Confirmed presence of the RAS mutation(s)

     Broad match: KRAS mutation (unspecified)Neoplasms

166. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

     Recruiting Phase 1 BeOne Medicines (BeiGene) Started 2025Primary completion 2028-08 NCT06589596

     BGB-58067BG-89894RAS(ON) Inhibitors

     documented RAS mutation status or KRAS mutation is required for selected cohorts

     Broad match: KRAS mutation (unspecified)Advanced Solid Tumor

167. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

     Recruiting Phase 1 Astellas Started 2025Primary completion 2028-11 NCT07094204

     ASP5834panitumumab

     …umor malignancy with a documented Kirsten rat sarcoma viral oncogene homolog (KRAS) G12V, G12D, G12C, G12R, G12A or G13D mutation or KRAS amplification (copy number \>/= 4) determined …

     Broad match: KRAS G12DSolid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

168. A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

     Recruiting Phase 1 PAQ Therapeutics Started 2025Primary completion 2028-10 NCT07300150

     PT0511cetuximab

     A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

     Broad match: KRAS mutation (unspecified)Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor

169. Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

     Not yet recruiting Phase 1 GeneCraft Started 2025Primary completion 2026-09 NCT06934590

     RX001

     Subjects with valid biopsy results documented the presence of KRAS mutation.

     Broad match: KRAS mutation (unspecified)Non-Small Cell Lung Cancer

170. Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

     Recruiting Phase 1 Sichuan University Started 2025Primary completion 2027-12 NCT07004244

     KRAS-mutated mRNA vaccinetoripalimabpemetrexedcarboplatin

     KRAS G12C/G12D/G12V/G13D mutation-positive by genomic testing.

     Broad match: KRAS G12DMalignant Tumors

171. Study of AUBE00 in Patients With Solid Tumors

     Recruiting Phase 1 Roche Started 2025Primary completion 2029-12 NCT07030959

     AUBE00cetuximab

     Patients with Kirsten rat sarcoma (KRAS) alteration confirmed by local tests or central laboratory test (Details are defined for each part)

     Broad match: KRAS mutation (unspecified)Solid Tumors

172. A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

     Recruiting Phase 1 Jiangsu Hengrui Started 2025Primary completion 2028-12 NCT07189949

     HRS-2329 Tablet

     A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

     Broad match: KRAS mutation (unspecified)Advanced Solid Tumors Harboring RAS Mutations or Amplifications

173. Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

     Recruiting Phase 1 University of Southern California Started 2025Primary completion 2027-01 NCT06336902

     balstilimabbotensilimab

     …cally confirmed microsatellite stable (MSS) metastatic colorectal adenocarcinoma with any KRAS mutation (as determined by a Clinical Laboratory Improvement Act \[CLIA\]-certified lab), includin…

     Broad match: KRAS mutation (unspecified)Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8

174. TLN-372 in Advanced KRAS Mutant Solid Tumors

     Recruiting Phase 1 Treeline Biosciences Started 2025Primary completion 2031-12 NCT07204340

     TLN-372cetuximabpembrolizumab

     Patients must have locally advanced or metastatic KRAS mutant solid tumors.

     Broad match: KRAS mutation (unspecified)KRAS Mutant Solid Tumors

175. KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

     Active, not recruiting Phase 1 Corregene Biotechnology Started 2025Primary completion 2028-11 NCT06767046

     KRAS-specific Autologous TCR-T cell injection

     KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

     Broad match: KRAS mutation (unspecified)Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)

176. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

     Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2024Primary completion 2028-11 NCT06625775

     BBO-10203trastuzumabfulvestrantribociclibFOLFOXbevacizumab

     …-positive advanced breast cancer (aBC), HR-positive/HER2-negative advanced breast cancer, KRAS mutant advanced colorectal cancer (aCRC), or KRAS mutant advanced non-small cell lung cancer (aN…

     Broad match: KRAS mutation (unspecified)Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors

177. A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

     Active, not recruiting Phase 1 Eli Lilly Started 2024Primary completion 2030-01 NCT06607185

     LY4066434.cetuximabnab-paclitaxelgemcitabineoxaliplatinleucovorinirinotecanfluorouracilcarboplatincisplatinpemetrexedpembrolizumab

     Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA

     Broad match: KRAS G12DPancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor

178. A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

     Active, not recruiting Phase 1 Amgen Started 2024Primary completion 2026-10 NCT06360354

     Anvumetostatgemcitabinenab-paclitaxelFOLFIRINOXdaraxonrasib

     Rat Sarcoma Viral Oncogene Homolog (RAS) mutation

     Broad match: KRAS mutation (unspecified)Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

179. Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor

     Recruiting Phase 1 Pharosgen Started 2024Primary completion 2026-12 NCT06944457

     MPD-1

     KRAS mutation or PTEN loss is confirmed in tumor tissues prior to screening, and there is a documented …

     Broad match: KRAS mutation (unspecified)Cancer, Solid Tumor Cancer, Biomarkers

180. A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

     Active, not recruiting Phase 1 Pfizer Started 2024Primary completion 2026-10 NCT06447662

     PF-07934040gemcitabinenab-paclitaxelcetuximabfluorouraciloxaliplatinleucovorinbevacizumabpembrolizumabpemetrexedcisplatinpaclitaxel

     Documentation of mutated KRAS gene

     Broad match: KRAS mutation (unspecified)Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung

181. KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

     Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2024Primary completion 2029-11 NCT06411691

     KRAS Vaccine with Poly-ICLC adjuvantbalstilimabbotensilimab

     Have one of the KRAS mutations included in the vaccine at the time of vaccination expressed in tumor.

     Broad match: KRAS mutation (unspecified)Colorectal Cancer, Pancreatic Cancer

182. NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

     Recruiting Phase 1 Georgetown University Started 2023Primary completion 2027-01 NCT05661201

     NEROFEdoxorubicin

     NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

     Broad match: KRAS mutation (unspecified)Solid Tumor, KRAS Mutation-Related Tumors

183. Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

     Recruiting Phase 1 Shanghai YingLi Pharmaceutical Started 2023Primary completion 2025-10 NCT06096974

     YL-17231

     Advanced solid tumors harboring mutations in KRAS, HRAS or NRAS as determined by laboratory testing, including local laboratory testing.

     Broad match: KRAS mutation (unspecified)Advanced Solid Tumors

184. CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

     Active, not recruiting Phase 1 Chinese PLA General Hospital Started 2023Primary completion 2026-06 NCT05631899

     KRAS-EphA-2-CAR-DCnab-paclitaxelcyclophosphamideAnti-PD-1 antibodyipilimumab

     … or cytology with documentation of tumor EphA2 positive (≥20%) and KRAS mutation (G12V or G12D or G12C) within 6 months prior to screening.

     Broad match: KRAS G12DSolid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C

185. A Study of Avutometinib for People With Solid Tumor Cancers

     Active, not recruiting Phase 1 Memorial Sloan Kettering Cancer Center Started 2023Primary completion 2029-10 NCT06104488

     avutometinib

     …ase pathway alterations including but not limited to BRAF/ARAF/CRAF fusions or mutations, KRAS/NRAS/HRAS alterations, PTPN11 or SOS1/2 mutations and/or loss of function alterations in NF1.

     Broad match: KRAS mutation (unspecified)Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood

186. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

     Recruiting Phase 1 Kura Oncology Started 2023Primary completion 2027-01 NCT06026410

     Darlifarnibcabozantinibadagrasib

     KRAS-mutant and/or amplified PDAC

     Broad match: KRAS mutation (unspecified)Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

187. A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

     Recruiting Phase 1 TYK Medicines Started 2023Primary completion 2025-10 NCT05866692

     TY-2699a

     …n cancer, small cell lung cancer, castrate-resistant prostate cancer (CRPC), or PDAC with KRAS mutant

     Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2023-11-07Solid Tumor, Adult

188. Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

     Recruiting Phase 1 National Cancer Institute (NCI) Started 2022Primary completion 2027-03 NCT05111561

     ZEN-3694binimetinib

     Solid tumor with genomic alteration(s) activating RAS signaling including activating KRAS, NRAS, HRAS, or BRAF mutations, inactivating NF1 mutations, or BRAF fusions

     Broad match: KRAS mutation (unspecified)Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma

189. Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

     Active, not recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2022Primary completion 2027-10 NCT05013216

     Cohort A: Patients at high risk of developing pancreatic cancer.Cohort B: Patients must have evidence of a pancreatic cystic neoplasm

     … Patients must have cystic fluid testing that demonstrates the presence of one of the six KRAS mutations included in the study vaccine.

     Broad match: KRAS mutation (unspecified)High Risk Cancer, Pancreatic Cancer

190. A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

     Recruiting Phase 1 MSD (Merck & Co.) Started 2021Primary completion 2030-02 NCT05067283

     calderasibpembrolizumabcarboplatinpemetrexedcetuximaboxaliplatinleucovorinfluorouracil

     A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

     Broad match: KRAS mutation (unspecified)Advanced Solid Tumors

191. A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

     Active, not recruiting Phase 1 HUYABIO International Started 2021Primary completion 2026-12 NCT05163028

     HBI-2376

     Advanced malignant solid tumors with KRAS or EGFR mutations diagnosed by histology or cytology

     Broad match: KRAS mutation (unspecified)Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor

192. AB122 Platform Study

     Recruiting Phase 1 Taiho Pharmaceutical Started 2021Primary completion 2027-06 NCT04999761

     zimberelimabTAS-116futibatinibTAS-115trifluridine/tipiracilramucirumabbevacizumabfluorouracilcisplatinAB154carboplatinnab-paclitaxel

     …ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type. \[Mutant is defined as at least KRAS or NRAS mutant (any exon, any mutation)\].

     Broad match: KRAS mutation (unspecified)Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer

193. A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

     Active, not recruiting Phase 1 Boehringer Ingelheim Started 2021Primary completion 2026-11 NCT04973163

     BI 1823911BI 1701963midazolam

     … and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

     Broad match: KRAS mutation (unspecified)Solid Tumors, KRAS Mutation

194. A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

     Recruiting Phase 1 RasCal Therapeutics Started 2021Primary completion 2026-12 NCT04678648

     RSC-1255 Dose EscalationRSC-1255 Dose Expansion

     Has either tissue agnostic tumors and documented RAS mutations or with glioblastoma with or without mutation in RAS

     Broad match: KRAS mutation (unspecified)Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer

195. Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

     Active, not recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2020Primary completion 2027-06 NCT04117087

     KRAS peptide vaccinenivolumabipilimumab

     …ecurrence or distant metastasis noted on imaging \> 12 months after the first dose of the mutant KRAS peptide vaccine with poly-ICLC adjuvant.

     Broad match: KRAS mutation (unspecified)Colorectal Cancer, Pancreatic Cancer

196. A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

     Active, not recruiting Phase 1 Boehringer Ingelheim Started 2019Primary completion 2027-03 NCT04111458

     BI 1701963trametinib

     Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening

     Broad match: KRAS mutation (unspecified)Solid Tumors, KRAS Mutation; SOS1

197. Phase I Trial of Defactinib and VS-6766.

     Active, not recruiting Phase 1 Institute of Cancer Research, United Kingdom Started 2017Primary completion 2023-04 NCT03875820

     avutometinibdefactinib

     …lly or cytologically proven advanced non-small-cell lung cancer (NSCLC) with a documented KRAS mutation, refractory to conventional treatment, or for which no conventional therapy exists or is …

     Broad match: KRAS mutation (unspecified)NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer

198. Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

     Recruiting Early Phase 1 Ruijin Hospital Started 2024Primary completion 2026-12 NCT06577532

     ABO2102toripalimab

     Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

     Broad match: KRAS mutation (unspecified)Pancreatic Neoplasms, Other Solid Tumors

199. Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

     Recruiting Early Phase 1 Ruijin Hospital Started 2024Primary completion 2026-06 NCT06496373

     Fixed neoantigen tumor vaccinepersonalized neoantigen tumor vaccinePD-1 inhibitor

     … neoantigen effectively presented by the patient's HLA type, including those derived from KRAS or TP53 mutations.

     Broad match: KRAS mutation (unspecified)Pancreatic Cancer Resectable, Chemotherapy-intolerant

200. Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer

     Recruiting Early Phase 1 Ruijin Hospital Started 2023Primary completion 2026-11 NCT05916261

     Personalized neoantigen tumor vaccine

     …tics analysis, at least one antigen effectively presented by self-HLA was found , such as KRAS or TP53 mutations and correspondingly presented HLA types

     Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2023-10-26Advanced Pancreatic Cancer

201. Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

     Recruiting Early Phase 1 Ruijin Hospital Started 2023Primary completion 2026-06 NCT05916248

     Personalized neoantigen tumor vaccinePD-1 inhibitor

     …tics analysis, at least one antigen effectively presented by self-HLA was found , such as KRAS or TP53 mutations and correspondingly presented HLA types

     Broad match: KRAS mutation (unspecified)Advanced Solid Tumor

202. Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

     Not yet recruiting No phase Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2026Primary completion 2026-10 NCT07396090

     eDC-KRAS vaccinetislelizumab

     Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

     Broad match: KRAS mutation (unspecified)Advanced Solid Tumor

203. An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

     Not yet recruiting No phase Liu Huang Started 2025Primary completion 2028-04 NCT06985316

     fruquintinib

     4)Previous gene testing results indicate positive RAS mutation

     Broad match: KRAS mutation (unspecified)CRC, Colorectal Cancer

204. Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

     Recruiting No phase Shanghai Jiao Tong University School of Medicine Started 2024Primary completion 2026-12 NCT06141369

     individualized mRNA neoantigen vaccine (mRNA-0523-L001)

     …they predict at least one antigen that is effectively presented by their own HLA, such as KRAS or TP53 mutations and corresponding HLA typing, see 1.4 for the rationale of the topic.

     Broad match: KRAS mutation (unspecified)Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor

205. MRD Monitoring in Colorectal Cancer Using ctDNA

     Recruiting No phase Masaryk Memorial Cancer Institute Started 2023Primary completion 2027-01 NCT07895459

     Presence of KRAS gene mutation (specifically G12 or G13 mutations) confirmed in the primary tumor tissue.

     Broad match: KRAS mutation (unspecified)Colorectal Neoplasms, Colorectal Cancer (Diagnosis), Minimal Residual Disease

206. Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness

     Not yet recruiting No phase Fudan University Started 2023Primary completion 2026-07 NCT05881746

     KRAS/NRAS/BRAF mutation or right-sidedness;

     Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2023-05-31Colorectal Carcinoma, Liver Metastases

207. Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer

     Recruiting No phase Technische Universität Dresden Started 2021Primary completion 2027-12 NCT04678583

     Colorectal cancer with RAS mutation (KRAS or NRAS)

     Broad match: KRAS mutation (unspecified)Status may be outdated, last updated 2024-06-13Colorectal Liver Metastasis